Cargando…
(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
BACKGROUND: Immune checkpoint inhibitor (ICI)-related myocarditis is a rare but potentially fatal adverse event that can occur following ICI exposure. Early diagnosis and treatment are key to improve patient outcomes. Somatostatin receptor-based positron emission tomography–CT (PET/CT) showed promis...
Autores principales: | Boughdad, Sarah, Latifyan, Sofiya, Fenwick, Craig, Bouchaab, Hasna, Suffiotti, Madeleine, Moslehi, Javid J, Salem, Joe-Elie, Schaefer, Niklaus, Nicod-Lalonde, Marie, Costes, Julien, Perreau, Matthieu, Michielin, Olivier, Peters, Solange, Prior, John O, Obeid, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543755/ https://www.ncbi.nlm.nih.gov/pubmed/34686542 http://dx.doi.org/10.1136/jitc-2021-003594 |
Ejemplares similares
-
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
por: Coukos, Alexander, et al.
Publicado: (2022) -
Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020) -
Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
por: Van Damme, Helena, et al.
Publicado: (2021) -
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
por: Keegan, Alissa, et al.
Publicado: (2020) -
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)